This new vaccine is expected to be long lasting and multivalent, protecting against 5 types of Influenza virus. It has also the advantage of being safe as it is devoid of genetic material.
iBET is one of the partners in this EU funded project which aims to develop Innovative Eco-Technologies for Resource Recovery from Wastewater
This is a key instrument in the continued partnership between the Structural Biology for Drug Discovery Unit at iBET in Oeiras and the Molecular Interactions and Biophysics Group at Merck in Darmstadt.
1st year results prove to be very promising: no adverse effects or rejection of the cells were observed in the 55 patients tested!
The nomination was announced during its 25th Meeting, held last May in Lausanne, Switzerland.
In her interview, Paula Alves explains the rational behind iNOVA4Health, its aims and the top-level research that is being carried out within the consortium. You can hear the interview here (in Portuguese)
The 2017 ESACT (European Society of Animal Cell Technology) Meeting took place in Lausanne (May 14-17) and focused on the theme "Cell technologies for innovative therapies".